Myeloid cell: CD14
Why Myeloid Cells?
Myeloid cells are versatile cells that perform numerous functions migrating to all sites in the body and armed with effector functions capable of killing pathogens and cancer. Myeloid Therapeutics is engineering myeloid cells so they can be deployed to kill cancer.
Myeloid cells have many potent anti-cancer activities
Myeloid Therapeutics has developed a first in class approach to treating cancer. Our platform harnesses the innate abilities of myeloid cells to engulf cancer cells, produce anti-tumor agents, promote anti-tumor adaptive immunity and alter the tumor microenvironment, culminating in cancer death.
Rapidly recruited into cancers and other pathological conditions
Myeloid cells are a major white blood cell population in circulating blood. Originating from stem cells in the bone marrow, they are constantly being delivered to the body via the circulation. Myeloid cells are then recruited selectively to sites of tissue injury, infection and cancer.
Chemokines attract myeloid cells
Myeloid ATAK™ Cell Clinical Programs
ATAK™ Cell Platform
Our ATAK™ (Activate Target Attack Kill) platform equips myeloid cells with a novel CAR design that triggers tumor-specific phagocytosis and secretion of proinflammatory cytokines, resulting in a hot tumor microenvironment and causing tumor cell death. In addition, ATAK™ myeloid cells sustain the ability to cross-present antigen, thereby generating a durable anti-tumor response by cytotoxic T cells. In preclinical in vitro and animal studies, our CD5-ATAK™ myeloid cells (MT-101) and HER2-ATAK™ myeloid cells (MT-102) have shown promising activity against T cell cancer and Ovarian cancer respectively.
Programs & Pipeline
Peripheral T cell Lymphoma
Gastric & Esophageal